University of Minnesota to Overhaul Research Protections
By Jennifer Couzin-Frankel,
Science
| 06. 15. 2015
More than a decade after a young man committed suicide during a psychiatric clinical trial at the University of Minnesota—and a bioethicist there spent years lobbying for changes to the school’s clinical trials system—the university is announcing major changes to how it oversees trials and protects its most vulnerable research subjects. Last week, the school released a 75-page document describing an effort to restructure its system and calm its critics. Changes include tighter conflict-of-interest rules; a larger institutional review board (IRB) whose members will be compensated; improved training for researchers working with vulnerable populations, such as the severely mentally ill; and a board of external advisers to monitor the university’s efforts.
The report comes after two damning reviews earlier this year: one by a group of experts appointed by the Association for the Accreditation of Human Research Protection Programs and the other by the state’s Office of the Legislative Auditor. The first report examined protections for university clinical trial participants. Among other things, it found that many IRB members did not regularly attend meetings during the first half of 2014—the...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jorge Barrera and Rachel Houlihan, CBC | 04.09.2024
A Canadian DNA laboratory knowingly delivered prenatal paternity test results that routinely identified the wrong biological fathers — ruling out the real dads — and left a trail of shattered lives around the globe, a CBC News investigation has found...